argenex (NASDAQ:ARGX) Price Target Raised to $1,037.00

argenex (NASDAQ:ARGX) had its price target upped by Oppenheimer from $1,014.00 to $1,037.00 in a research report sent to investors on Friday,Benzinga reports. They currently have an outperform rating on the stock.

ARGX has been the topic of several other research reports. Wells Fargo & Company upped their target price on shares of argenex from $1,260.00 to $1,291.00 and gave the stock an “overweight” rating in a research note on Monday, June 1st. Morgan Stanley raised their target price on argenex from $1,170.00 to $1,180.00 and gave the stock an “overweight” rating in a research report on Wednesday, June 24th. Glj Research raised shares of argenex to a “strong-buy” rating in a report on Friday, April 3rd. Royal Bank Of Canada raised their target price on shares of argenex from $945.00 to $1,025.00 and gave the company an “outperform” rating in a research note on Friday. Finally, Citizens Jmp decreased their price objective on argenex from $944.00 to $932.00 and set a “market outperform” rating on the stock in a research report on Friday. Two analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $1,050.50.

argenex Price Performance

Shares of argenex stock opened at $918.22 on Friday. The company’s fifty day simple moving average is $868.28 and its two-hundred day simple moving average is $815.22. The firm has a market cap of $57.44 billion, a PE ratio of 35.26, a price-to-earnings-growth ratio of 1.21 and a beta of 0.45. argenex has a 12-month low of $587.37 and a 12-month high of $953.58.

argenex (NASDAQ:ARGX) last announced its earnings results on Tuesday, July 21st. The company reported $7.32 EPS for the quarter, beating analysts’ consensus estimates of $5.86 by $1.46. argenex had a return on equity of 43.59% and a net margin of 32.19%.The company had revenue of $1.54 billion during the quarter, compared to the consensus estimate of $1.45 billion. As a group, sell-side analysts expect that argenex will post 26.95 earnings per share for the current fiscal year.

Institutional Investors Weigh In On argenex

Institutional investors and hedge funds have recently modified their holdings of the company. Eastern Bank purchased a new position in shares of argenex during the 2nd quarter valued at approximately $32,000. Sound Income Strategies LLC acquired a new stake in shares of argenex during the 4th quarter worth approximately $28,000. Whipplewood Advisors LLC purchased a new stake in argenex in the first quarter valued at $28,000. Sunbelt Securities Inc. purchased a new position in argenex during the third quarter worth about $36,000. Finally, Axiom Investment Management LLC acquired a new position in shares of argenex in the 1st quarter worth approximately $50,000. Institutional investors and hedge funds own 60.32% of the company’s stock.

argenex News Summary

Here are the key news stories impacting argenex this week:

• Positive Sentiment: argenex reported Q2 EPS of $7.32, topping estimates, on revenue of $1.54 billion versus expectations of $1.45 billion, highlighting strong operating momentum and profitability. Q2 earnings report and conference call
• Positive Sentiment: Reuters reported that global sales of Vyvgart jumped in the second quarter, a key driver for argenex’s growth and a major reason the stock has been gaining investor attention. Reuters article on Vyvgart sales
• Positive Sentiment: Oppenheimer, RBC, and Guggenheim all raised price targets and maintained bullish ratings, signaling increased Street confidence in argenex’s growth trajectory and pipeline prospects.
• Positive Sentiment: A Seeking Alpha note highlighted surging profitability, robust cash generation, and operational leverage, while pointing to pipeline catalysts such as empasiprubart as additional upside potential. Seeking Alpha rating upgrade article
• Neutral Sentiment: Short-interest data showed 0 shares reported, which provides little actionable signal for investors because the figures appear unchanged and unusually low.
• Negative Sentiment: Citizens JMP trimmed its price target slightly from $944 to $932, though it still kept a positive rating, making this more of a minor caution than a bearish call.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.